Off-label drug helps one boy with autism speak, parents say: Experts want more data by Céline Gounder edited by Sadie Harley, reviewed by Andrew Zinin Editors' notes ...
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback